Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/2/2025

Iron Deficiency and Cardiac Palpitations

Mechanisms and Clinical Significance

  • Iron deficiency can directly cause cardiac palpitations through multiple mechanisms, including compensatory cardiac response, direct myocardial effects, and hyperdynamic circulation, even in the absence of anemia 1, 2
  • The European Society of Cardiology recommends evaluating iron status in all newly diagnosed heart failure patients, as iron deficiency affects 40-70% of chronic heart failure patients and is recognized as an important comorbidity independent of anemia 4
  • Iron deficiency in heart failure patients is associated with worse symptoms, reduced exercise capacity, and increased hospitalizations 5

Diagnostic Approach

  • Iron deficiency is defined as ferritin <100 μg/L OR ferritin 100-299 μg/L with transferrin saturation <20% in heart failure patients, and should be evaluated using ferritin and transferrin saturation simultaneously 4

Treatment Considerations

  • Intravenous iron is preferred over oral supplementation in heart failure patients with iron deficiency, as it bypasses hepcidin-mediated blockade of intestinal absorption, and improves exercise capacity, quality of life, and reduces hospitalizations 5, 6
  • The European Society of Cardiology gives a Class IIa recommendation for IV iron therapy in heart failure patients with reduced ejection fraction and iron deficiency 6
  • Oral iron supplementation is first-line for patients without cardiovascular disease, with ferrous sulfate 324 mg (65 mg elemental iron) daily or twice daily between meals, and treatment should continue for 2-3 months after hemoglobin normalization to replenish iron stores 6

Important Caveats

  • Erythropoiesis-stimulating agents should be avoided in patients with mild to moderate anemia and heart disease, as harms outweigh benefits 7, 2
  • Patients with pre-existing cardiac conditions should be monitored more closely when starting iron supplementation 3
  • IV iron should be withheld during active infections, as these patients were excluded from clinical trials 8